Revenue
2018
2019
2020
2021
2022
2023
2024
2025
ZEVRA THERAPEUTICS, INC. (ZVRA)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $106.5M | $23.6M | $27.5M | $10.2M | $28.6M | $13.3M | $12.8M | $0 | — | — | $0 | $0 | $0 |
| Research & development | $12.7M | $42.1M | $39.8M | $19.8M | $10.2M | $8.8M | $19.4M | $41.8M | $20.6M | $20.5M | $13.9M | $11.9M | $3.4M |
| Operating expenses | — | — | — | — | — | — | — | $55.9M | $33.4M | $37.5M | $22.8M | $16.4M | $4.7M |
| Operating income | −$62.9M | −$87.0M | −$49.6M | −$42.6M | $7.7M | −$5.6M | −$20.3M | −$55.9M | −$33.4M | −$37.5M | −$22.8M | −$16.4M | −$4.7M |
| EBITDAderived | −$58.9M | −$80.6M | −$48.6M | −$41.6M | $8.0M | −$5.3M | −$20.0M | −$55.6M | −$33.0M | −$37.3M | −$22.7M | −$16.4M | −$4.7M |
| Net income | $83.2M | −$105.5M | −$46.0M | −$26.8M | −$8.6M | −$12.8M | −$24.5M | −$56.5M | −$43.4M | −$16.5M | −$54.7M | −$24.5M | −$5.2M |
| Basic EPSper diluted share | $1.40 | -$2.28 | -$1.30 | -$0.78 | -$2.11 | -$3.21 | -$13.23 | -$3.15 | -$2.96 | -$1.13 | -$7.42 | -$10.27 | -$2.20 |
| Diluted EPSper diluted share | $1.35 | -$2.28 | — | — | -$2.11 | -$3.21 | -$13.23 | -$3.15 | -$2.96 | -$1.13 | -$7.42 | -$10.27 | -$2.20 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 22, 2026Form 4 · 10b5-1 | Thompson RahsaanChief Legal & Compliance | SellCommon Stock | 34.6K | $12.68 | $438.2K | 80.2K |
| May 11, 2026Form 4 · 10b5-1 | Thompson RahsaanChief Legal & Compliance | SellCommon Stock | 1.8K | $11.30 | $20.3K | 48.1K |
| Feb 9, 2026Form 4 · 10b5-1 | McFarlane Neil F.President and CEO | SellCommon Stock | 14.6K | $8.56 | $125.2K | 387.2K |
| Feb 3, 2026Form 4 · 10b5-1 | Schafer JoshuaCCO | SellCommon Stock | 10.5K | $9.19 | $96.5K | 62.3K |
| Feb 3, 2026Form 4 · 10b5-1 | Sangiovanni Timothy J.SVP, Finance & Corp Controller | SellCommon Stock | 3.0K | $9.18 | $27.5K | 29.6K |